Tag
NYSE: JNJ
- InnoCare Pharma gains Chinese IND approval for dual-target IBD antibody ICP‑B161
- Johnson & Johnson reports at least 72% PASI 90 after two years
- Cullinan Therapeutics begins FDA submission for zipalertinib combination
- Lung cancer innovations showcased at ASCO 2026 as researchers pursue earlier detection
- U.S. tariffs on Chinese medical devices threaten global supply chains
- Johnson & Johnson subsidiary sued for USD$147M for breaching antitrust rules in California
- CG Oncology shares jump on positive clinical trial data for cancer drug
- Five startups taking aim at cancer diagnosis and treatment
- Robotic-assist and other tech spark demand in lung cancer surgery market
- Johnson & Johnson may bankrupt a subsidiary to pay USD$6.9B talcum cancer settlements